{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:27:48Z","timestamp":1772166468569,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T00:00:00Z","timestamp":1569196800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T00:00:00Z","timestamp":1569196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      Extended spectrum \u03b2-lactamases (ESBL) producing Enterobacteriaceae predominantly\n                      <jats:italic>E. coli<\/jats:italic>\n                      and\n                      <jats:italic>K. pneumoniae<\/jats:italic>\n                      bacteremia have limited treatment options and high mortality. The objective was to determine the risk factors for in-hospital mortality particularly treatment with carbapenem versus beta lactam\/beta lactamase combination (BL\/BLI) in patients with ceftriaxone resistant\n                      <jats:italic>E. coli<\/jats:italic>\n                      bacteremia. A retrospective cohort study was conducted at the Aga Khan University, Karachi, Pakistan. Adult patients with sepsis and monomicrobial ceftriaxone resistant\n                      <jats:italic>E. coli<\/jats:italic>\n                      bacteremia were enrolled. Factors associated with mortality in patients were determined using logistic regression analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mortality rate was 37% in those empirically treated with carbapenem compared to 20% treated with BL\/BLI combination therapy (p-value: 0.012) and was 21% in those treated with a carbapenem compared to 13% in patients definitively treated with BL\/BLI combination therapy (p-value: 0.152). In multivariable logistic regression analysis, only Pitt bacteremia score of\u2009\u2265\u2009four was significantly associated with mortality (OR: 7.7 CI 2.6\u201322.8) while a urinary source of bacteremia was protective (OR: 0.26 CI 0.11\u20130.58). In-hospital mortality in patients with Ceftriaxone resistant\n                      <jats:italic>E. coli<\/jats:italic>\n                      bacteremia did not differ in patients treated with either a carbapenem or BL\/BLI combination. However, Pitt bacteremia score of \u2265\u20094 was strongly associated with mortality.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13104-019-4648-7","type":"journal-article","created":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T09:02:42Z","timestamp":1569229362000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Risk factors for mortality of patients with ceftriaxone resistant E. coli bacteremia receiving carbapenem versus beta lactam\/beta lactamase inhibitor therapy"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1610-8748","authenticated-orcid":false,"given":"Nosheen","family":"Nasir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samrah","family":"Razi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safia","family":"Awan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Faisal","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,23]]},"reference":[{"issue":"12","key":"4648_CR1","doi-asserted-by":"publisher","first-page":"6235","DOI":"10.3390\/ijerph10126235","volume":"10","author":"N Allocati","year":"2013","unstructured":"Allocati N, Masulli M, Alexeyev MF, Di Ilio C. Escherichia coli in Europe: an overview. Int J Environ Res Public Health. 2013;10(12):6235\u201354.","journal-title":"Int J Environ Res Public Health"},{"issue":"4","key":"4648_CR2","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1097\/QCO.0b013e3283398dc1","volume":"23","author":"J Oteo","year":"2010","unstructured":"Oteo J, Perez-Vazquez M, Campos J. Extended-spectrum [beta]-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis. 2010;23(4):320\u20136.","journal-title":"Curr Opin Infect Dis"},{"issue":"3","key":"4648_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.4103\/0974-777X.68531","volume":"2","author":"D Rawat","year":"2010","unstructured":"Rawat D, Nair D. Extended-spectrum beta-lactamases in gram negative bacteria. J Glob Infect Dis. 2010;2(3):263\u201374.","journal-title":"J Glob Infect Dis"},{"issue":"4","key":"4648_CR4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jhin.2009.02.021","volume":"73","author":"ME Falagas","year":"2009","unstructured":"Falagas ME, Karageorgopoulos DE. Extended-spectrum beta-lactamase-producing organisms. J Hosp Infect. 2009;73(4):345\u201354.","journal-title":"J Hosp Infect"},{"issue":"4","key":"4648_CR5","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","volume":"18","author":"DL Paterson","year":"2005","unstructured":"Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18(4):657\u201386.","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"4648_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S1473-3099(08)70041-0","volume":"8","author":"JD Pitout","year":"2008","unstructured":"Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8(3):159\u201366.","journal-title":"Lancet Infect Dis"},{"key":"4648_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13756-018-0309-1","volume":"7","author":"S Abrar","year":"2018","unstructured":"Abrar S, Hussain S, Khan RA, Ul Ain N, Haider H, Riaz S. Prevalence of extended-spectrum-beta-lactamase-producing Enterobacteriaceae: first systematic meta-analysis report from Pakistan. Antimicrob Resist Infect Control. 2018;7:26.","journal-title":"Antimicrob Resist Infect Control"},{"key":"4648_CR8","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1186\/s12879-014-0659-0","volume":"14","author":"J Zhang","year":"2014","unstructured":"Zhang J, Zheng B, Zhao L, Wei Z, Ji J, Li L, et al. Nationwide high prevalence of CTX-M and an increase of CTX-M-55 in Escherichia coli isolated from patients with community-onset infections in Chinese county hospitals. BMC Infect Dis. 2014;14:659.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"4648_CR9","first-page":"108","volume":"54","author":"P Kumar","year":"2016","unstructured":"Kumar P, Ranotkar S, Zutshi S, Lahkar M, Phukan C, et al. Prevalence and identification of extended spectrum beta-lactamases (ESBL) in Escherichia coli isolated from a tertiary care hospital in North-East India. Indian J Exp Biol. 2016;54(2):108\u201314.","journal-title":"Indian J Exp Biol"},{"issue":"4","key":"4648_CR10","first-page":"1379","volume":"31","author":"S Fatima","year":"2018","unstructured":"Fatima S, Muhammad IN, Khan MN, Jamil S. Phenotypic expression and prevalence of multi drug resistant extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae in Karachi, Pakistan. Pak J Pharm Sci. 2018;31(4):1379\u201384.","journal-title":"Pak J Pharm Sci"},{"issue":"10","key":"4648_CR11","first-page":"436","volume":"55","author":"K Jabeen","year":"2005","unstructured":"Jabeen K, Zafar A, Hasan R. Frequency and sensitivity pattern of extended spectrum beta lactamase producing isolates in a tertiary care hospital laboratory of Pakistan. J Pak Med Assoc. 2005;55(10):436\u20139.","journal-title":"J Pak Med Assoc"},{"issue":"7","key":"4648_CR12","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ajic.2015.02.030","volume":"43","author":"T Chopra","year":"2015","unstructured":"Chopra T, Marchaim D, Johnson PC, Chalana IK, Tamam Z, Mohammed M, et al. Risk factors for bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: a focus on antimicrobials including cefepime. Am J Infect Control. 2015;43(7):719\u201323.","journal-title":"Am J Infect Control"},{"issue":"12","key":"4648_CR13","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1128\/AAC.48.12.4574-4581.2004","volume":"48","author":"CI Kang","year":"2004","unstructured":"Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, et al. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother. 2004;48(12):4574\u201381.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"4648_CR14","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ijantimicag.2018.06.018","volume":"52","author":"A Russo","year":"2018","unstructured":"Russo A, Falcone M, Gutierrez-Gutierrez B, Calbo E, Almirante B, Viale PL, et al. Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum beta-lactamase-producing Enterobacteriaceae. Int J Antimicrob Agents. 2018;52(5):577\u201385.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"4648_CR15","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/jac\/dkw402","volume":"72","author":"SE Battle","year":"2017","unstructured":"Battle SE, Bookstaver PB, Justo JA, Kohn J, Albrecht H, Al-Hasan MN. Association between inappropriate empirical antimicrobial therapy and hospital length of stay in Gram-negative bloodstream infections: stratification by prognosis. J Antimicrob Chemother. 2017;72(1):299\u2013304.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"4648_CR16","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1001\/jama.2018.12163","volume":"320","author":"PNA Harris","year":"2018","unstructured":"Harris PNA, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M, et al. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E. coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA. 2018;320(10):984\u201394.","journal-title":"JAMA"},{"issue":"12","key":"4648_CR17","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1093\/jac\/dks301","volume":"67","author":"KZ Vardakas","year":"2012","unstructured":"Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 2012;67(12):2793\u2013803.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"4648_CR18","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1128\/AAC.00607-13","volume":"57","author":"M McLaughlin","year":"2013","unstructured":"McLaughlin M, Advincula MR, Malczynski M, Qi C, Bolon M, Scheetz MH. Correlations of antibiotic use and carbapenem resistance in Enterobacteriaceae. Antimicrob Agents Chemother. 2013;57(10):5131\u20133.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"4648_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/cid\/cir790","volume":"54","author":"J Rodriguez-Bano","year":"2012","unstructured":"Rodriguez-Bano J, Navarro MD, Retamar P, Picon E, Pascual A. Extended-spectrum beta-lactamases-Red Espanola de Investigacion en Patologia Infecciosa\/Grupo de Estudio de Infeccion Hospitalaria G. beta-Lactam\/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis. 2012;54(2):167\u201374.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"4648_CR20","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1097\/CCM.0000000000003119","volume":"46","author":"MM Levy","year":"2018","unstructured":"Levy MM, Evans LE, Rhodes A. The surviving sepsis campaign bundle: 2018 update. Crit Care Med. 2018;46(6):997\u20131000.","journal-title":"Crit Care Med"},{"issue":"5","key":"4648_CR21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.ijantimicag.2019.03.007","volume":"53","author":"MM Sfeir","year":"2019","unstructured":"Sfeir MM. Post-MERINO trial: any role for piperacillin-tazobactam in treating bloodstream infections caused by extended-spectrum beta-lactamase producing Enterobacteriaceae? Int J Antimicrob Agents. 2019;53(5):557\u20138.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"4648_CR22","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.ijantimicag.2018.07.021","volume":"52","author":"MM Sfeir","year":"2018","unstructured":"Sfeir MM, Askin G, Christos P. Beta-lactam\/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis. Int J Antimicrob Agents. 2018;52(5):554\u201370.","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"4648_CR23","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1111\/1469-0691.12085","volume":"19","author":"MN Al-Hasan","year":"2013","unstructured":"Al-Hasan MN, Lahr BD, Eckel-Passow JE, Baddour LM. Predictive scoring model of mortality in Gram-negative bloodstream infection. Clin Microbiol Infect. 2013;19(10):948\u201354.","journal-title":"Clin Microbiol Infect"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-019-4648-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13104-019-4648-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-019-4648-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T19:16:28Z","timestamp":1600715788000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-019-4648-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,23]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4648"],"URL":"https:\/\/doi.org\/10.1186\/s13104-019-4648-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.12475\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.12475\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.12475\/v2","asserted-by":"object"}]},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,23]]},"assertion":[{"value":"27 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical exemption was obtained from the Aga Khan University\u2019s Ethics Review Committee with Reference number: (2734-MED-ERC-13).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"611"}}